CDT Equity (NASDAQ:CDT) Shares Scheduled to Reverse Split on Monday, July 20th

CDT Equity Inc. (NASDAQ:CDT)’s stock is set to reverse split before the market opens on Monday, July 20th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 19th.

CDT Equity Trading Up 1.1%

CDT stock traded up $0.00 during midday trading on Thursday, reaching $0.35. 888,099 shares of the company traded hands, compared to its average volume of 19,030,332. CDT Equity has a 52-week low of $0.30 and a 52-week high of $461.54. The business has a 50 day moving average of $0.92 and a 200-day moving average of $12.33.

CDT Equity (NASDAQ:CDT) last posted its quarterly earnings data on Wednesday, July 15th. The company reported ($5.56) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CDT. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. Wall Street Zen cut shares of CDT Equity to a “strong sell” rating in a research report on Saturday, June 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, CDT Equity has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.